Which statement about empagliflozin's indication is true?

• A. It is used only for type 2 diabetes.
• B. It is not approved for chronic kidney disease.
• C. It is indicated for chronic kidney disease, type 2 diabetes, and heart failure.
• D. It has no effect on cardiovascular outcomes.

Answer: (C)

Empagliflozin provides cardiovascular and renal benefits beyond just lowering blood glucose, which is why its approved uses include more than type 2 diabetes alone. As an SGLT2 inhibitor, it has been shown in clinical trials to slow the progression of chronic kidney disease and reduce heart failure-related outcomes, including in patients who do not have diabetes. These results have led to labeling that covers chronic kidney disease, type 2 diabetes, and heart failure.

That broad indication is why this option is true: empagliflozin is indicated for CKD, T2DM, and heart failure. It is not limited to diabetes, and it does have demonstrated cardiovascular benefit, so the other statements don’t fit.